#None #Bausch + Lomb #Bausch Health #Salix

Bausch Health Reports Impressive Q3 2026 Financial Results

Bausch Health Companies Inc. recently released its financial results for the third quarter of 2026, showcasing a remarkable performance that has caught the eyes of investors and analysts alike. With consolidated revenues reaching $2.94 billion, the company experienced a substantial growth of 10% on a reported basis and 8% on an organic basis when compared to the same period from the previous year.

Chief Executive Officer Thomas J. Appio highlighted that the organization has successfully delivered its fourteenth consecutive quarter of revenue and Adjusted EBITDA growth. Perhaps more notably, the Adjusted EBITDA, excluding contributions from Bausch + Lomb, surpassed the $1 billion mark for the first time, reflecting robust operational execution across the company's diverse portfolio.

In terms of profitability, the net income attributable to Bausch Health stood at $436 million, marking a significant increase from the $179 million reported in Q3 of 2025. This translates to earnings of $1.15 per diluted share, which is a substantial leap from the previous year's figure of $0.48. Adjusted earnings per diluted share also saw an impressive 53% increase, climbing from $1.16 to $1.77.

Revenue Breakdown

The company provided a detailed breakdown of revenue performance across its various segments. Here’s a closer look:

• - Total Bausch Health Revenues: $2,941 million in Q3 2026, up from $2,681 million in Q3 2025, reflecting a 10% growth.
• - Bausch Health (excluding B+L): Revenues rose to $1,566 million, a 12% increase year-on-year.
• - Salix segment: Revenues increased by 16% to $831 million, primarily driven by growth in Xifaxan®.
• - International segment: Revenue climbed to $299 million, a 5% increase compared to the previous year.
• - Solta Medical segment: Revenue enhanced by 18% to $165 million, aided by a strategic acquisition in China.
• - Diversified segment: Revenue grew 5% reaching $271 million, with strong performances particularly in dermatology.
• - Bausch + Lomb segment: Revenue was reported at $1,375 million, an increase of 7% over the same quarter last year.

This diverse growth across various segments underscores the company’s strong operational management and strategic direction, showcasing its resilience in a competitive marketplace.

Cash Flow and Debt Management

Bausch Health generated $581 million in cash from operating activities during the quarter, underscoring its ability to generate liquidity. This healthy cash generation allowed the company to reduce net debt by over $500 million, a testament to its ongoing commitment to strengthening its balance sheet.

Furthermore, the Board of Directors has authorized a $50 million share repurchase program aimed at offsetting dilution associated with the expected vesting of management equity awards in 2027. Appio noted that this move reflects Bausch Health's focus on enhancing shareholder value while continuing to prioritize operational efficiency and sustainable growth.

Full-Year Guidance Update

In light of its successful Q3 performance, Bausch Health has raised its full-year guidance for 2026. The updated projections suggest that total revenues will be between $10.975 billion and $11.175 billion, with Adjusted EBITDA expected to be between $4.315 billion and $4.415 billion, representing a growth of 12% to 14% compared to the prior year.

This positive outlook is due, in part, to the anticipated impact of tariffs affecting operations. Appio expressed confidence in the trajectory of the company's growth, underpinning that their strategic initiatives and operational focus position Bausch Health well for long-term success.

Conclusion

Bausch Health's third-quarter results reflect a company poised for continued growth and resilience in the healthcare sector. With its focus on operational excellence and value creation, the future looks promising as it navigates the dynamic market landscape. Investors and stakeholders can look forward to more advancements as the company continues to execute its strategic priorities in the coming quarters.